Swiss Biotech Center and Cellect sign a strategic agreement
At the end of July 2018, the Israeli company Cellect Biotherapeutics signed an exclusive strategic production agreement with the Swiss Biotech Center (SBC).
Cellect Biotherapeutics Ltd has entered into an exclusive strategic manufacturing and supply agreement with the Swiss Biotech Center (SBC).
Cellect Biotherapeutics Ltd, the developer of a novel stem cell production technology from Israel, has entered into a strategic manufacturing and supply agreement with the Swiss Biotech Center (SBC), securing the exclusive production of the FasCELLECT protein for the next five years.
The FasCELLECT protein is a key active ingredient in Cellect’s technology for cell separation and functional selection of stem cells. “This partnership with SBC is a major achievement for our company in securing the production and flow of our key ingredient for US based clinical trials and collaborations with clinical centers”, comments Dr. Shai Yarkoni, CEO of Cellect.
Cellect Biotherapeutics has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of stem cell-based therapies.